Financial Ratios Bio-Rad Laboratories, Inc.
Stocks
BIO
US0905722072
Medical Equipment, Supplies & Distribution
|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 286.62 USD | -1.99% |
|
-2.51% | -5.30% |
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Profitability | ||||||||||
Return on Assets | 2.25 | 1.94 | 1.77 | 1.55 | 1.67 | |||||
Return on Total Capital | 2.89 | 2.44 | 2.16 | 1.86 | 1.98 | |||||
Return On Equity % | 36.06 | -31.14 | -6.94 | -24.09 | 10.84 | |||||
Return on Common Equity | 36.06 | -31.14 | -6.94 | -24.09 | 10.84 | |||||
Margin Analysis | ||||||||||
Gross Profit Margin % | 56.99 | 55.97 | 53.56 | 53.73 | 52.01 | |||||
SG&A Margin | 29.19 | 29.43 | 30.86 | 31.72 | 31.74 | |||||
EBITDA Margin % | 23.54 | 22.28 | 19.15 | 16.39 | 16.71 | |||||
EBITA Margin % | 19.93 | 18.26 | 14.58 | 11.31 | 11.23 | |||||
EBIT Margin % | 18.96 | 17.38 | 13.69 | 10.48 | 10.3 | |||||
Income From Continuing Operations Margin % | 145.28 | -129.45 | -23.86 | -71.86 | 29.42 | |||||
Net Income Margin % | 145.28 | -129.45 | -23.86 | -71.86 | 29.42 | |||||
Net Avail. For Common Margin % | 145.28 | -129.45 | -23.86 | -71.86 | 29.42 | |||||
Normalized Net Income Margin | 12.17 | 11.19 | 10.05 | 7.49 | 7.72 | |||||
Levered Free Cash Flow Margin | 16.76 | 1.63 | 4.65 | 7.05 | 9.93 | |||||
Unlevered Free Cash Flow Margin | 16.8 | 2.48 | 5.81 | 8.24 | 11.12 | |||||
Asset Turnover | ||||||||||
Asset Turnover | 0.19 | 0.18 | 0.21 | 0.24 | 0.26 | |||||
Fixed Assets Turnover | 4.21 | 4.01 | 3.81 | 3.63 | 3.69 | |||||
Receivables Turnover (Average Receivables) | 6.93 | 6.1 | 5.43 | 5.45 | 5.66 | |||||
Inventory Turnover (Average Inventory) | 2.1 | 1.91 | 1.65 | 1.54 | 1.65 | |||||
Short Term Liquidity | ||||||||||
Current Ratio | 2.92 | 5.55 | 5.83 | 6.48 | 5.62 | |||||
Quick Ratio | 1.9 | 4.04 | 4.03 | 4.55 | 3.89 | |||||
Operating Cash Flow to Current Liabilities | 0.96 | 0.34 | 0.72 | 0.97 | 1.03 | |||||
Days Sales Outstanding (Average Receivables) | 52.64 | 59.8 | 67.2 | 67.13 | 64.51 | |||||
Days Outstanding Inventory (Average Inventory) | 173.44 | 191.04 | 220.67 | 237.38 | 220.94 | |||||
Average Days Payable Outstanding | 42.55 | 36.61 | 39.21 | 41.85 | 37.58 | |||||
Cash Conversion Cycle (Average Days) | 183.53 | 214.23 | 248.66 | 262.66 | 247.87 | |||||
Long Term Solvency | ||||||||||
Total Debt/Equity | 1.63 | 14.44 | 16.08 | 20.93 | 18.58 | |||||
Total Debt / Total Capital | 1.61 | 12.62 | 13.85 | 17.3 | 15.67 | |||||
LT Debt/Equity | 1.36 | 14.05 | 15.61 | 20.27 | 18.08 | |||||
Long-Term Debt / Total Capital | 1.34 | 12.28 | 13.45 | 16.76 | 15.24 | |||||
Total Liabilities / Total Assets | 23.11 | 28.78 | 28.93 | 29.85 | 29.53 | |||||
EBIT / Interest Expense | 357.27 | 12.78 | 7.4 | 5.5 | 5.43 | |||||
EBITDA / Interest Expense | 475.91 | 17.81 | 11.63 | 10.02 | 10.17 | |||||
(EBITDA - Capex) / Interest Expense | 398.02 | 14.85 | 8.46 | 6.64 | 6.96 | |||||
Total Debt / EBITDA | 0.3 | 2.05 | 2.44 | 2.8 | 2.78 | |||||
Net Debt / EBITDA | -0.88 | -0.59 | -0.35 | -0.59 | -0.31 | |||||
Total Debt / (EBITDA - Capex) | 0.36 | 2.45 | 3.36 | 4.24 | 4.06 | |||||
Net Debt / (EBITDA - Capex) | -1.05 | -0.71 | -0.48 | -0.89 | -0.46 | |||||
Growth Over Prior Year | ||||||||||
Total Revenues, 1 Yr. Growth % | 14.81 | -4.12 | -4.67 | -3.92 | 0.65 | |||||
Gross Profit, 1 Yr. Growth % | 15.85 | -5.69 | -8.77 | -3.36 | -3.59 | |||||
EBITDA, 1 Yr. Growth % | 25.22 | -11.16 | -18.03 | -13.05 | -2.09 | |||||
EBITA, 1 Yr. Growth % | 32.77 | -13.75 | -23.88 | -19.75 | -6.57 | |||||
EBIT, 1 Yr. Growth % | 34.74 | -13.83 | -24.88 | -20.37 | -7.95 | |||||
Earnings From Cont. Operations, 1 Yr. Growth % | 11.55 | -185.27 | -82.43 | 189.38 | -141.2 | |||||
Net Income, 1 Yr. Growth % | 11.55 | -185.27 | -82.43 | 189.38 | -141.2 | |||||
Normalized Net Income, 1 Yr. Growth % | 40.97 | -13.5 | -14.42 | -23.39 | -3.16 | |||||
Diluted EPS Before Extra, 1 Yr. Growth % | 11.38 | -186.48 | -82.08 | 199.56 | -142.61 | |||||
Accounts Receivable, 1 Yr. Growth % | 0.98 | 16.79 | -1.14 | -7.46 | 1.79 | |||||
Inventory, 1 Yr. Growth % | -8.04 | 25.7 | 8.51 | -2.63 | -2.54 | |||||
Net Property, Plant and Equip., 1 Yr. Growth % | 0.32 | -5.15 | 6.5 | -4.85 | 3.09 | |||||
Total Assets, 1 Yr. Growth % | 37.03 | -24.15 | -8.91 | -23.86 | 12.95 | |||||
Tangible Book Value, 1 Yr. Growth % | 39.17 | -32.16 | -9.8 | -26.75 | 14.22 | |||||
Common Equity, 1 Yr. Growth % | 38.33 | -29.74 | -9.09 | -24.85 | 13.46 | |||||
Cash From Operations, 1 Yr. Growth % | 14.11 | -70.96 | 92.85 | 21.42 | 16.92 | |||||
Capital Expenditures, 1 Yr. Growth % | 22.12 | -15.67 | 38.92 | 5.68 | -4.83 | |||||
Levered Free Cash Flow, 1 Yr. Growth % | 24.45 | -91.32 | 2.11K | 69.27 | 32.59 | |||||
Unlevered Free Cash Flow, 1 Yr. Growth % | 20.52 | -86.81 | 427.02 | 53.52 | 28.17 | |||||
Compound Annual Growth Rate Over Two Years | ||||||||||
Total Revenues, 2 Yr. CAGR % | 12.44 | 4.92 | -4.4 | -4.3 | -1.66 | |||||
Gross Profit, 2 Yr. CAGR % | 15.11 | 4.44 | -7.24 | -6.2 | -3.1 | |||||
EBITDA, 2 Yr. CAGR % | 37.5 | 5.58 | -14.65 | -17.63 | -8.15 | |||||
EBITA, 2 Yr. CAGR % | 51.69 | 6.79 | -18.96 | -24.38 | -13.71 | |||||
EBIT, 2 Yr. CAGR % | 55.33 | 7.5 | -19.53 | -25.34 | -14.68 | |||||
Earnings From Cont. Operations, 2 Yr. CAGR % | 55.38 | -2.48 | -61.3 | -28.7 | 9.2 | |||||
Net Income, 2 Yr. CAGR % | 55.38 | -2.48 | -61.3 | -28.7 | 9.2 | |||||
Normalized Net Income, 2 Yr. CAGR % | 55.82 | 10.07 | -13.96 | -21.38 | -13.81 | |||||
Diluted EPS Before Extra, 2 Yr. CAGR % | 55.31 | -1.87 | -60.64 | -26.74 | 12.98 | |||||
Accounts Receivable, 2 Yr. CAGR % | 3.86 | 8.6 | 7.45 | -4.36 | -2.95 | |||||
Inventory, 2 Yr. CAGR % | 1.63 | 7.52 | 16.79 | 2.79 | -2.58 | |||||
Net Property, Plant and Equip., 2 Yr. CAGR % | -0.39 | -1.01 | 0.51 | 0.66 | -0.96 | |||||
Total Assets, 2 Yr. CAGR % | 48.98 | 2.02 | -16.87 | -16.72 | -7.27 | |||||
Tangible Book Value, 2 Yr. CAGR % | 56.34 | -2.76 | -21.77 | -18.71 | -8.53 | |||||
Common Equity, 2 Yr. CAGR % | 54.1 | -1.35 | -20.08 | -17.34 | -7.66 | |||||
Cash From Operations, 2 Yr. CAGR % | 19.74 | -42.35 | -25.17 | 53.02 | 19.15 | |||||
Capital Expenditures, 2 Yr. CAGR % | 10.73 | 1.92 | 8.23 | 21.16 | 0.29 | |||||
Levered Free Cash Flow, 2 Yr. CAGR % | 24.55 | -67.36 | -49.42 | 694.88 | 43.67 | |||||
Unlevered Free Cash Flow, 2 Yr. CAGR % | 21.88 | -60.35 | -43.54 | 181.53 | 36.05 | |||||
Compound Annual Growth Rate Over Three Years | ||||||||||
Total Revenues, 3 Yr. CAGR % | 8.48 | 6.63 | 1.62 | -4.24 | -2.68 | |||||
Gross Profit, 3 Yr. CAGR % | 10.72 | 7.66 | -0.16 | -6.06 | -5 | |||||
EBITDA, 3 Yr. CAGR % | 27.57 | 19.71 | -2.96 | -15.71 | -11.37 | |||||
EBITA, 3 Yr. CAGR % | 38.02 | 26.45 | -4.62 | -21.2 | -17.02 | |||||
EBIT, 3 Yr. CAGR % | 42.06 | 28.47 | -4.61 | -21.9 | -17.99 | |||||
Earnings From Cont. Operations, 3 Yr. CAGR % | 126.46 | 27.29 | -44.92 | -24.32 | -40.61 | |||||
Net Income, 3 Yr. CAGR % | 126.46 | 27.29 | -44.92 | -24.32 | -40.61 | |||||
Normalized Net Income, 3 Yr. CAGR % | 43.39 | 28.87 | 1.21 | -19.06 | -13.77 | |||||
Diluted EPS Before Extra, 3 Yr. CAGR % | 126.48 | 27.86 | -44.33 | -22.57 | -38.85 | |||||
Accounts Receivable, 3 Yr. CAGR % | 2.57 | 8 | 5.25 | 2.23 | -2.35 | |||||
Inventory, 3 Yr. CAGR % | -0.67 | 9.09 | 7.85 | 9.92 | 0.98 | |||||
Net Property, Plant and Equip., 3 Yr. CAGR % | 11 | -1.04 | 1.43 | -1.31 | 1.47 | |||||
Total Assets, 3 Yr. CAGR % | 46.87 | 19.02 | -1.76 | -19.27 | -7.82 | |||||
Tangible Book Value, 3 Yr. CAGR % | 52.73 | 18.42 | -5.17 | -23.47 | -8.95 | |||||
Common Equity, 3 Yr. CAGR % | 50.36 | 18.66 | -4 | -21.7 | -8.14 | |||||
Cash From Operations, 3 Yr. CAGR % | 31.99 | -24.84 | -13.78 | -12.07 | 39.89 | |||||
Capital Expenditures, 3 Yr. CAGR % | -2.37 | 4.61 | 13.01 | 7.38 | 11.79 | |||||
Levered Free Cash Flow, 3 Yr. CAGR % | 54.47 | -47.54 | -33.77 | -28.07 | 347.52 | |||||
Unlevered Free Cash Flow, 3 Yr. CAGR % | 49.17 | -40.55 | -29.42 | -24.28 | 120.81 | |||||
Compound Annual Growth Rate Over Five Years | ||||||||||
Total Revenues, 5 Yr. CAGR % | 7.16 | 5.34 | 3.13 | 2.11 | 0.29 | |||||
Gross Profit, 5 Yr. CAGR % | 7.87 | 5.68 | 3.12 | 1.87 | -1.35 | |||||
EBITDA, 5 Yr. CAGR % | 18.7 | 15.7 | 9.07 | 2.94 | -5.07 | |||||
EBITA, 5 Yr. CAGR % | 25.89 | 22.82 | 11.94 | 2.77 | -8.36 | |||||
EBIT, 5 Yr. CAGR % | 30.04 | 26.16 | 13.6 | 3.21 | -8.77 | |||||
Earnings From Cont. Operations, 5 Yr. CAGR % | 177.08 | 97 | 11.76 | 0.95 | -27.58 | |||||
Net Income, 5 Yr. CAGR % | 177.08 | 97 | 11.76 | 0.95 | -27.58 | |||||
Normalized Net Income, 5 Yr. CAGR % | 32.92 | 29.49 | 17.34 | 5.59 | -5.08 | |||||
Diluted EPS Before Extra, 5 Yr. CAGR % | 175.85 | 97.33 | 12.52 | 2.32 | -26.11 | |||||
Accounts Receivable, 5 Yr. CAGR % | 2.61 | 1.25 | 4.5 | 2.88 | 1.89 | |||||
Inventory, 5 Yr. CAGR % | 1.74 | 3.87 | 5.98 | 6.53 | 3.55 | |||||
Net Property, Plant and Equip., 5 Yr. CAGR % | 7.32 | 6.61 | 7.31 | -0.36 | 0.47 | |||||
Total Assets, 5 Yr. CAGR % | 35.79 | 25.87 | 16.99 | 3.18 | -4 | |||||
Tangible Book Value, 5 Yr. CAGR % | 46.44 | 31.59 | 16.9 | 1.87 | -6.53 | |||||
Common Equity, 5 Yr. CAGR % | 39.59 | 26.83 | 16.8 | 2.68 | -5.48 | |||||
Cash From Operations, 5 Yr. CAGR % | 24.89 | 13.3 | 5.6 | -0.12 | -1.87 | |||||
Capital Expenditures, 5 Yr. CAGR % | -3.1 | 0.26 | 3.83 | 10.94 | 7.74 | |||||
Levered Free Cash Flow, 5 Yr. CAGR % | 33.25 | -0.81 | -1.33 | -10.55 | -9.72 | |||||
Unlevered Free Cash Flow, 5 Yr. CAGR % | 30.37 | 15.96 | 0.97 | -8.54 | -8.24 |
- Stock Market
- Stocks
- BIO Stock
- Financials Bio-Rad Laboratories, Inc.
- Financial Ratios
Select your edition
All financial news and data tailored to specific country editions
















